Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Preliminary Tests, Confirmatory Tests), By Type (Adenocarcinoma, Interstitial cell carcinoma, Others), By End use (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Prostate Cancer Diagnostics Market, valued at USD 8.92 Billion in 2024, is projected to experience a CAGR of 9.25% to reach USD 15.17 Billion by 2030. Prostate cancer diagnostics encompass a suite of medical procedures and tests employed for the detection, characterization, and staging of prostate cancer, including prostate-specific antigen blood tests, digital rectal examinations, various imaging modalities, and biopsy procedures. The market's expansion is primarily propelled by an aging global demographic, the increasing incidence and prevalence of prostate cancer, growing public awareness coupled with enhanced screening initiatives, and continuous technological advancements in diagnostic methodologies.

According to the International Agency for Research on Cancer (IARC) and World Health Organization (WHO), in 2022, there were an estimated 1.5 million new cases of prostate cancer globally. A significant challenge impeding market growth is the substantial cost associated with advanced diagnostic technologies, which can limit accessibility and adoption, particularly in regions with developing healthcare infrastructures.

Key Market Drivers

The increasing global incidence of prostate cancer significantly propels the diagnostics market, as healthcare systems contend with a growing disease burden. This rising prevalence necessitates more frequent and advanced screening, early detection methods, and ongoing monitoring strategies. According to the American Cancer Society, in its January 2024 "Cancer Statistics, 2024" report, nearly 300,000 new cases of prostate cancer were expected in the United States during the year, highlighting the persistent diagnostic demand. An aging male population, inherently at higher risk, further exacerbates the need for robust diagnostic tools globally.

Concurrently, advancements in diagnostic technologies are revolutionizing the market by offering enhanced accuracy and less invasive options. Innovations in imaging, biomarker identification, and artificial intelligence powered analysis improve the detection of clinically significant cancers. For example, according to Ibex Medical Analytics, in its February 2025 news release regarding "FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic", its AI-powered Ibex Prostate Detect software assisted in identifying 13% of cancer cases missed by pathologists diagnosing without the AI tool, demonstrating technology's direct impact on precision. This progress attracts considerable investment and fosters competitive development within the market, a trend further reflected by funding initiatives. According to the Prostate Cancer Foundation, in March 2024, it announced over $21 million in funding for innovative prostate cancer research as part of its 2023 Challenge Awards, underscoring a sustained commitment to enhancing diagnostic capabilities.

Download Free Sample Report

Key Market Challenges

A significant impediment to the expansion of the Global Prostate Cancer Diagnostics Market is the considerable cost associated with advanced diagnostic technologies. These high costs place a substantial financial burden on healthcare systems and individual patients, particularly in regions with developing healthcare infrastructures where budgets are often constrained and reimbursement mechanisms may be insufficient for specialized procedures. This economic barrier directly impacts the ability of healthcare providers to procure and deploy necessary diagnostic equipment and expertise, thus limiting the availability of comprehensive diagnostic services.

The financial strain imposed by these advanced technologies subsequently restricts their accessibility and widespread adoption. This directly hampers market growth as a considerable segment of the global population, particularly in resource-limited settings, is unable to access timely and accurate prostate cancer diagnosis. According to the American Hospital Association, in 2023, medical supply expenses collectively accounted for $146.9 billion, an increase of $6.6 billion over 2022. The substantial upfront costs for critical equipment and device upgrades present a significant financial challenge for hospitals, thereby impeding investment in new medical technology and broader deployment of advanced diagnostics. This restricted access leads to delayed diagnoses, which in turn impacts treatment outcomes and reduces the overall market potential for diagnostic solutions.

Key Market Trends

The Global Prostate Cancer Diagnostics Market is significantly influenced by the decentralization of diagnostic services to outpatient and home settings. This trend represents a fundamental shift in healthcare delivery, moving away from traditional hospital-centric models towards more accessible and convenient diagnostic options. The adoption of at-home collection methods for prostate cancer screening is gaining traction, driven by advancements in non-invasive testing. For instance, in February 2025, Lynx Dx announced the commercial launch of MyProstateScore 2.0 for at-home collection by patients, a test designed to accurately predict the risk of clinically significant prostate cancer using urine samples collected without a digital rectal exam. This development enhances patient convenience, broadens access to screening, and aligns with the growing preference for patient-centered care. Such decentralization helps alleviate the burden on hospital infrastructure while offering patients greater flexibility in managing their diagnostic pathways.

Another impactful trend reshaping the market is the expansion of genomic and advanced biomarker testing. These sophisticated diagnostic tools offer a more precise understanding of prostate cancer, moving beyond conventional methods to provide detailed molecular insights. Such testing enables improved risk stratification, identifies aggressive forms of cancer, and guides personalized treatment decisions. According to the 2023 Canadian Urological Association guideline, in a study with patients in Canada, the prevalence of germline mutations using a targeted panel of 22 DNA damage repair genes in liquid biopsies from unselected patients with metastatic prostate cancer was 6.5%. The increasing integration of genetic information into diagnostic pathways is exemplified by companies like 23andMe, which in March 2024, launched new genetic risk reports for its 23andMe+ members, offering insights into individual prostate cancer risk based on polygenic risk scores. This expansion supports tailored prevention strategies and treatment optimization, thus driving demand for advanced molecular diagnostics.

Segmental Insights

The Confirmatory Tests segment is experiencing rapid growth within the Global Prostate Cancer Diagnostics Market. This accelerated expansion is primarily driven by the increasing global incidence of prostate cancer, which necessitates accurate diagnostic validation following initial screenings. Advancements in biomarker and genomic testing, alongside enhanced imaging techniques such as transrectal ultrasound and multiparametric MRI, provide more precise disease characterization and risk assessment. Furthermore, the growing integration of artificial intelligence in analyzing diagnostic images and biopsy samples significantly improves accuracy and efficiency, thereby bolstering the demand for these crucial confirmatory procedures for definitive diagnosis and treatment planning.

Regional Insights

North America leads the global prostate cancer diagnostics market due to its highly developed healthcare infrastructure and high patient awareness regarding regular screening programs. The region benefits from early adoption of advanced diagnostic technologies and favorable reimbursement policies, particularly in the United States, which enhance access to comprehensive diagnostic procedures. Furthermore, robust regulatory support from bodies such as the U. S. Food and Drug Administration (FDA) facilitates the swift introduction of innovative diagnostic tools, including AI-powered solutions, further solidifying North America's dominant market position.

Recent Developments

• In August 2025, Artera received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for ArteraAI Prostate. This AI-powered software is the first of its kind authorized to predict long-term outcomes for patients with non-metastatic prostate cancer. The authorization establishes ArteraAI Prostate as an FDA-regulated Software as a Medical Device, creating a new product code category for future AI-powered digital pathology risk-stratification tools. This technology can now be implemented at the point of diagnosis in qualified pathology laboratories across the U.S., enhancing personalized cancer care.

• In April 2025, OncoAssure launched its OncoAssure Prostate Test in the U.S. market. This next-generation prognostic tool is specifically designed to support clinical decision-making for men diagnosed with localized prostate cancer. The test helps assess the risk of aggressive disease and potential recurrence, applicable at key points in the prostate cancer pathway, including post-biopsy and post-surgery. Commercialized in the U.S. through a partnership with DiaCarta Inc., this diagnostic integrates genomic insights to offer a powerful solution for personalized patient management within the Global Prostate Cancer Diagnostics Market.

• In February 2025, Ibex Medical Analytics received 510(k) clearance from the FDA for its Ibex Prostate Detect software. This AI-powered digital pathology solution is designed to assist in identifying small and rare prostate cancers within tissue biopsies. The software analyzes whole slide images of prostate core needle biopsies, generating heat maps that highlight potentially malignant areas. It alerts pathologists to suspicious regions that may have been overlooked during initial assessments. This clearance marks a significant milestone for Ibex Medical Analytics in providing advanced diagnostic tools to enhance the accuracy and efficiency of prostate cancer detection.

• In September 2024, Nanostics Inc. and Protean BioDiagnostics Inc. announced a partnership to introduce CDX Prostate in the United States. This collaboration aims to provide a blood-based diagnostic tool that utilizes AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will offer the validated CDX Prostate risk score to healthcare providers, assisting men in making informed decisions about proceeding with a biopsy after a high prostate-specific antigen (PSA) test result or an abnormal digital rectal exam. This initiative represents a significant advancement in prostate cancer screening by providing critical support for personalized patient management.

Key Market Players

• MDx Health, Inc.
• Myriad Genetics, Inc.
• Abbott Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Siemens Healthcare AG
• OPKO Health, Inc.
• Exact Sciences Corporation
• Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Prostate Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Prostate Cancer Diagnostics Market, By Test Type:

o   Preliminary Tests

o   Confirmatory Tests

• Prostate Cancer Diagnostics Market, By Type:

o   Adenocarcinoma

o   Interstitial cell carcinoma

o   Others

• Prostate Cancer Diagnostics Market, By End use:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Prostate Cancer Diagnostics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prostate Cancer Diagnostics Market.

Available Customizations:

Global Prostate Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Prostate Cancer Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]